Ocugen, Inc. and Kwangdong Pharmaceutical Co., Ltd. Complete License Agreement of OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in Korea

Stock Information for Ocugen, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Ocugen, Inc.

Ocugen CEO to Present at NobleCon21-Noble Capital Markets' Twenty-First Annual Emerging Growth Equity Conference
Ocugen to Participate in H.C. Wainwright 27th Annual Global Investment Conference & Biotech on Tap 2025
Ocugen, Inc. Announces Positive Scientific Advice from the European Medicines Agency Related to the Approval Pathway for OCU410ST-Modifier Gene Therapy for Stargardt Disease
Ocugen, Inc. Announces Closing of $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen, Inc. Announces $20 Million Registered Direct Offering of Common Stock and Warrants
Ocugen Provides Business Update with Second Quarter 2025 Financial Results
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST-Novel Modifier Gene Therapy Candidate for Stargardt Disease

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.